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Alzheimer's  disease  is  a  complex  neurodegenerative  disorder 
characterized by memory and cognitive impairment and is the leading cause of 
dementia in the elderly. The aim of our study was to examine the polymorphic 
DNA markers CCR2 (+190 G/A), CCR5∆32, TNF-α (-308 G/A), TNF-α (-863 
C/A)  and  CALHM1  (+394  C/T)  to  determine  the  relationship  between  these 
polymorphisms and the risk of late onset Alzheimer's disease in the population of 
Eastern  Azerbaijan  of  Iran.    A  total  of  160  patient  samples and  163  healthy 
controls  were  genotyped  by  PCR-RFLP  and  the  results  confirmed  using 
bidirectional sequencing. 
Statistical analysis of obtained data revealed non-significant difference between 
frequency  of  CCR5∆32  in  case  and  control  groups.  The  same  result  was 
observed  for TNF-α (-863 C/A)  genotype  and  allele  frequencies. Contrary  to 
above results, significant differences were detected in frequency of TNF-α (-308 
G/A) and CCR2-64I genotypes between the cases and healthy controls. A weak 
significant  difference  observed  between  allele  and  genotype  frequencies  of 
rs2986017 in CALHM1 (+394 C/T; P86L) in patient and control samples.   
It can be concluded that the T allele of P86L variant in CALHM1 & +190 G/A 
allele  of  CCR2  have  a  protective  role  against  abnormal  clinical  features  of 
Alzheimer's disease. 
Key  words:  Alzheimer  disease;  CCR2;  CCR5;  CALHM1;  TNF-α;  Eastern 
Azerbaijan. 
INTRODUCTION 
Alzheimer's disease (AD), originally described by Alois Alzheimer in 1907, is the most 
common cause of dementia in the elderly. According to age at onset, two major types of AD are 504                                                                                                             GENETIKA, Vol. 45, No.2,503-514,2013 
generally differentiated: Early-onset (<60  years) familial AD (EOFAD) following Mendelian 
inheritance and late-onset AD (LOAD) or so-called ‘‘sporadic’’ cases with less apparent or no 
familial  aggregation  usually  occurring  later  in  life  (≥60  years).  However  this  traditional 
dichotomization is overly simplistic as there are cases of early-onset AD without evidence for 
Mendelian transmission while, conversely, LOAD is frequently observed with a strong familial 
clustering, sometimes resembling a Mendelian pattern (BERTRAM et al. 2010; RUBIO-PEREZ and 
MORILLAS-RUIZ 2012). 
Neurodegenerative  disorders  such  as  AD  and  also  for  many  of  the  other 
neurodegenerative  diseases,  familial  aggregation  was  already  recognized  as  a  salient  feature 
decades  before  any  of  the  underlying  molecular  genetics  and  biochemical  properties  were 
known. The cause of AD is principally genetic but also environmental, all mostly unknown. As a 
matter of fact, it was often only the identification of specific, disease-segregating mutations in 
previously unknown genes that directed the attention of molecular biologists to certain proteins 
and  pathways  that  are  now  considered  crucial  in  the  development  of  the  various 
neurodegenerative diseases (BERTRAM et al. 2012; ZLOKOVIC 2011). 
The etiology of LOAD is complex and it has strong genetic heterogeneity (PASTOR and 
GOATE 2004; TUPPO and ARIAS 2005). Furthermore, the genetic component of this form is itself 
complex and heterogeneous: complex because there is no single or simple model explaining the 
mode of disease transmission and heterogeneous because the gene mutations or polymorphisms 
may interact with one another and with environmental factors (LAMBERT and AMOUYEL 2011). 
Therefore  studying  of  any  candidate  gene  can  help  to  identify  the  heterogeneous  nature  of 
LOAD in different populations.  
The genetics of LOAD has taken impressive steps forwards in the last few years. To 
date, more than six-hundred genes have been linked to the disorder. However, only a minority of 
them  are  supported  by  a  sufficient  level  of  evidence  (OLGIATI  et  al.  2011).  These  studies 
identified several new susceptibility genes including Tumor necrosis factor-alpha (TNF- α), C-C 
chemokine  receptor  type  2(CCR2),  C-C  chemokine  receptor  type  5  (CCR5)  and  Calcium 
homeostasis modulator 1 (CALHM1).   
TNF  plays  a  critical  role  in  brain  development,  brain  physiology,  synaptic  plasticity,  sleep, 
circadian  rhythm  and  normal  behavior.  Serum  concentrations  of  TNF-α  were  found  to  be 
elevated in Alzheimer patients (BONOTIS et al. 2008). The gene product is an important pro 
inflammatory  cytokine  and  activates  the  nuclear  factor  kappa  B  (NF-KB),  a  protein  which 
activates the secretion of Apo lipoprotein E (APOE). APOE gene located on chromosome 19 is 
the only recognized susceptibility gene for this form of Alzheimer (BALES et al. 2000; SESHADRI 
et  al.  2010).  Polymorphisms  in  the  promoter  region  of  TNF-α  gene  have  been  reported  to 
increase the transcription rate of the gene and thus might influence the risk of AD (FELDMANN 
and MAINI 2003; TEDDE et al 2008). Amongst them the polymorphisms located on -308bp and -
836bp have been shown to be associated with an increased and decreased transcriptional activity 
of the gene respectively (FARGION et al. 2004). 
CCR2  signaling  can  mediate  accumulation  of  microglia  at  sites  affected  by 
neuroinflammation. CCR2 and its main ligand CCL2 (MCP-1) might also be involved in the 
altered metabolism of Aβ (HARRIES et al. 2012; NAERT and RIVEST 2012; WESTIN et al. 2012). 
The G to A single nucleotide polymorphism at position 190 of the CCR2 gene causes a change 
from  valine  to  isoleucine  at  codon  64  (CCR2-64I)  in  the  first  transmembrane  region  of  the 
protein resulting in an impaired protein product with lost function. J GHARESOURAN et al:   DNA MARKERS ASSOCIATED WITH LATE ALZHEIMER DISEASE               505 
There  is  growing  evidence  that  chemokines  and  their  receptors  are  upregulated  in 
reactive microglial cells in the brain tissue of affected individuals, and they may play a role in 
the recruitment and accumulation of microglial cells at Aβ sites in senile plaques. Indeed, some 
immunohistochemical studies have shown that the activated microglial cells in both control and 
patients present an increased expression of chemokine receptor CCR5, indicating to important 
role of CCR5 receptor in regulation of brain immune response in AD. Recently it has been 
suggested  that  CCR5∆32  polymorphism  has  a  protective  effect  towards  some  inflammatory 
diseases such as AD. 
Tissue  Info  studies  (SKRABANEK  and  CAMPAGNE  2001)  and  the  Alzgene  database 
(BERTRAM et al. 2007) have introduced the gene Calcium homeostasis modulator 1 (CALHM1; 
MIM# 612234), located about 1.6 Mb apart from LOAD marker D10S1671 on chromosome 10, 
as  one  of  the  candidate  genes  for  LOAD  (Bertram  et  al.  2000).  CALHM1  is  preferentially 
expressed in the hippocampus, a brain region which is affected early in the course of AD. The 
multipass  transmembrane  glycoprotein  encoded  by  CALHM1,  controls  cytosolic  Ca
2+ 
concentrations in brain cells. In in vitro experiments, CALHM1 expression promotes calcium 
influx, and triggers a decrease in amyloid β levels, along with an elevation of soluble APPα 
levels  that  appears  to  be  regulated  by  calcium  influx  (DRESES-WERRINGLOER  et  al.  2008). 
Substitution  of  proline  with  leucine  at  codon  86  (P86L)  results  in  the  SNP  rs2986017  in 
CALHM1. A recent study has reported that this variant of CALHM1 increases the risk of AD by 
40% (DRESES-WERRINGLOER et al. 2008). Functional studies have shown that the rs2986017 SNP 
results in decreased permeability to calcium ions and lowered calcium ion levels, ultimately 
leading to an increase in Aß peptide (AQDAM et al. 2010).  
Although many LOAD associated genes have been identified, the replication studies 
play a critical role in confirming the reported data, especially within different ethnic populations. 
The present study was conducted to reveal the possible association of polymorphisms of above 
mentioned  genes  in  the  population  of  eastern  Azerbaijan  of  Iran.  Similar  results  had  been 
reported for a number of ethnicities when the present study was started; however no published 
data was present about the population investigated in our study.  
 
 
MATERIALS AND METHODS 
Design, Setting, and Participant 
Reported information from investigations of genetic association of LOAD with SNPs 
located in the candidate gene regions was collected from a recent large genome-wide association 
study (GWAS) conducted by the Alzheimer Disease Genetics Consortium (ADGC). Our study 
included 160 AD patients (94 women & 66 men) and 163 healthy controls (95 women & 68 
men). The age of patient group at onset was ranged within 65-99 years (mean age 76.06 ±7.75 
years).  
The samples for control group was selected from a distinguish lab by matching the 
same ethnicity to subject  group with an age at  onset ranging within 65-89  years (mean age 
75.29±6.75 years). All Alzheimer subjects were diagnosed by expert clinicians according to the 
DSM-IV criteria (AMERICAN PSYCHIATRIC ASSOCIATION, 1994; THE DEMENTIA STUDY GROUP OF 
THE  ITALIAN  NEUROLOGICAL  SOCIETY  2000).  The  sporadic  form  of  the  disease  was  ensured 
where no affected individuals were present in first degree relatives of subjects and the age of 
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Gene selection 
We tested the genetic association of LOAD with three genes encoding the inflammatory 
pathway factors and with one other Calcium homeostasis modulator gene. The Tumor necrosis 
factor alpha, CCR2, CCR5 and CALHM1 genes have included in this study.  
 
Table 1. PCR primers complementary to the studied variation 
 
Sample Preparation, Genotyping and quality control of genotype data 
Blood specimens were collected in sterile tubes containing EDTA, and the DNA was 
extracted using the salting out method. The PCR reactions was prepared in a total volume of 25 
µl, containing 0.1 micrograms of genomic DNA, 0.01 µg each of primers, 2.5 µl of 10×PCR 
buffer (670 mM Tris-HCl pH 8.8, 160 mM (NH4)2SO4, 0.1%Tween-20), dNTP mix (10mM 
each), 50 mM MgCl
2, Taq DNA polymerase (5000u/ml). The primer designing was carried out 
using an online program (Primer 3) and Ensembl Genome Browser for blasting. Cycles of PCR 
reactions were optimized employing the online software of mutation discovery. The primers and J GHARESOURAN et al:   DNA MARKERS ASSOCIATED WITH LATE ALZHEIMER DISEASE               507 
PCR conditions for each of the polymorphic DNA fragments have been summarized in table 1. 
The PCR or RFLP products were fractionated on an 8% acrylamide gel and visualized flowing to 
staining by AgNO3.  
 
Association analysis  
The CCR5∆32 (32 bp deletion, nt794; chromosome 3p21) genotype was determined by 
PCR without RFLP. The PCR produced a 220bp product from the wild type allele and an 188bp 
product from the deleted allele. The conditions of RFLP reactions for each of the remaining 
polymorphisms have been shown in table 2.  
 
Table 2: Digestion conditions of amplified DNA fragments  
Product 
name 
NCBI SNP 
ID 
Restriction 
enzyme 
Digestion 
conditions 
Size of Fragments after 
digestion(bp) 
CCR2 
rs1799864 
(3p21) 
BsejI  65°C for 1-16 
171 for wild 
152+19 for mutant 
TNFa 
(-308G/A) 
rs1800629 
(6P21) 
NcoI  37°C for 1-16 
126 and 18 for wild 
126 for mutant 
TNFa 
(-863G/A) 
rs1800630 
(6P21) 
TaiI  65°C for 12-16 
125 for wild 
104+21 for mutant 
CALHM1 
rs2986017 
(10q24) 
AluI  37°C for 1-16 
122 and 19 for wild 
144 for mutant 
 
 
Heterogeneity study and gene-based multiple testing correction 
The allelic and genotypic frequencies were obtained by direct counting. Data analysis 
was performed using SPSS16. Chi square and  Fisher’s exact test were used to compare the 
genotypes. Statistical significance was set at P< 0.05. The odds ratio (OR) was calculated at 95% 
CI. 
RESULTS  
Case-control analysis, full sample 
In this study the control group was matched by age, gender, race and education to the 
subjects. There was no major departure of the genotypes from the Hardy–Weinberg equilibrium. 
Table 3 shows the results obtained from statistical analysis of mentioned variables, indicating to 
non-significant differences between the two groups.  
Only 1.3% of Alzheimer patients were homozygous for the CCR2-64I allele compared 
to  12.9%  in  normal controls,  indicating to  association  of  decreased  frequency  of  CCR2-64I 
polymorphism with AD (Table 4). 508                                                                                                             GENETIKA, Vol. 45, No.2,503-514,2013 
Table 3. Comparasion of mean age, sex and education levels between AD cases and control subjects using 
t-test and χ
2 test anylysis 
 
Table4. Statically analysis results for association of AD with SNPs in CCR2, CCR5, TNFa and CALHM1 in 
Individuals 
Gene/SNP  MA  MAF  MA-OR(95% CI) 
w/m + m/m frequencies 
OR (95% CI)  P Value 
a 
CCR2 
rs1799864 
A  P < 0.001 
4.5 
(2.78-7.29) 
4.78 
(2.83-7.94) 
P < 0.001 
CCR5 
rs333 
-  0.26 
0.67 
(0.33-1.35) 
0.65 
(0.32-1.35) 
0.25 
TNFa 
rs1800629 
A  P < 0.001 
0.08 
(0.04-0.13) 
0.067 
(0.03-0.11) 
P < 0.001 
TNFa 
rs1800630 
A  0.27 
0.68 
(0.34-1.35) 
0.65 
(0.32-1.35) 
0.25 
CALHM1  
rs2986017 
T  0.003 
0.4 
(0.22-0.74) 
0.41 
(0.22-0.79) 
0.008 
Abbreviations: AD, Alzheimer disease; MA, minor allele; MAF, w, wild type; m, mutant; weighted-average minor allele 
frequency; OR, odds ratio; SNP, single-nucleotide polymorphism. 
a: P values and ORs estimated under an additive model using logistic regression with covariates (adjusted for age, and 
sex) in a cognitively normal controls. Generalized linear models were used to estimate case-control data, and generalized 
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Amplification  of  CCR5  (∆32)  by  PCR  demonstrated  a  single  band  of  220bp  in 
individuals  homozygous  for  the  wild-type  allele  and  two  bands  of  220  and  188bp  in 
heterozygotes. No homozygous mutant subject was detected in this study. Table 4 shows non-
significant difference between the case and control groups for the polymorphic region of the 
CCR5 gene.  
The statistical analysis of patients, genotypes and allele frequencies (Table 4) revealed a 
significant  difference in  TNF-α,  -308  G/A  genotype  and allele frequencies  between  the  AD 
patients and healthy subjects. Non-significant difference was detected between TNF-α -863 C/A 
genotype and allele frequencies between AD patients and healthy controls (Table 4). 
The  allele  and  genotype  frequency  distribution  of  P86L  genotype  were  weakly 
significant between the two study groups (Table 4). As the difference between distribution of T 
allele (mutant)  in case and control groups is significant, it indicates to linkage of this allele with 
AD. 
 
DISCUSSION 
On the basis of the data obtained in previous studies, the recruitment of microglial cells in 
senile plaques is induced by chemokines and their up regulated receptors in AD brain (AKIYAMA 
et al. 2000; BAJETTO et al. 2002; FELDMANN and MAINI 2003). Aβ deposition is associated with a 
local inflammatory response, which is initiated by the activation and migration of microglia in 
inflammatory sites (DEAN et al. 2000, SHARMA et al. 2012).  
As  CCR2  is  located  about  19Kb  apart  from  CCR5  gene  on  chromosome  3,  the  co-
segregation  or  independent  assortment  of  the  two  markers  was  studied  in  case  and  control 
groups. CCR2-64I carriers were never found to be homozygous for the CCR5∆32, confirming 
almost complete linkage disequilibrium of the two markers.  
In our study population, occurrence of CCR2-64I polymorphism is decreased in AD patients 
indicating to association with low risk of developing the disease (P <0.001; OR=4.5, 95% CI: 
2.78-7.29). The low frequency of the genotype 64I/64I in AD patients proves real protective 
effect of this polymorphism on AD (P<0.001; OR=4.78, 95% CI: 2.83-7.94).  Our finding about 
this  polymorphism  covered  the  results  of  Galimberti  et  al  carried  out  on  Italian  population 
(P=0.037;  OR=0.65,  95%  CI:  0.41–1.03).  The  conclusion  drawn  from  this  study  is  also 
comparable  to  those  obtained  by  Huerta  et  al.  performed  on  Spanish  population  (P>0.05; 
OR=1.06, 95% CI: 0.57–1.96) (HUERTA et al.  2004).  
The statistical analysis of the data obtained in our study revealed non-significant difference 
in genetic distribution of CCR5 polymorphism between the case and control groups (P=0.25; 
OR=0.67,  95%  CI:  0.33-1.35).  Also,  the  haplotypes  of  CCR5∆32/∆32  were  never  observed 
either in AD or in control group. These observations are in agreement with the results reported 
for Italic ethnicity (P>0.05; OR=1.54, 95% CI: 0.97–2.45) (GALIMBERTI et al. 2004). 
Most of the recent studies have shown fundamental molecular differences in CC chemokine 
functions  according  to  origin  of  population.  Regarding  this,  distribution  of  CCR2-64I 
polymorphism in our study population is in agreement with previously reported findings, while 
the frequency of the CCR5∆32 allele emerged with a slight decrease compared to Caucasians. 
However, this mutation was shown to be significantly different in allelic distribution among 
Caucasians, Asian and Africans, even within close ethnic groups (WANG et al. 2003; FAVOROVA 
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The–308 polymorphism has been associated with an increased transcriptional activity and 
TNF-α  release,  whereas  the  –863  polymorphism  have  been  associated  with  a  reduced 
transcriptional activity.  In the  present  study  the  -308G/A  polymorphism  was  shown  to  be  a 
genetic marker for susceptibility to AD in Azeri Turk population (P<0.001; OR=0.067, 95% CI: 
0.03-0.11). Our results are similar to the results came out for the other ethnic groups (MOHADDES 
et  al.  2011).  A  report  about  the  population  of  Southern  China  suggests  that  the  -308G/A 
polymorphism of TNF-α gene might be a risk factor for AD in this ethnicity. Similar results have 
been reported for the Chilean population (DI et al. 2004). The association of -863 polymorphism 
with AD was not approved in the present study. This finding had been previously reported by 
others (P=0.24; OR=1.24, 95% CI: 0.86–1.85) (DI et al. 2004). Studies in Spain and Italy have 
also reported that there is no association between TNF- α -863C/A and AD. 
Regarding to the different roles of -308 G/A and -863 C/A polymorphisms on the levels of 
TNF-α transcription, a negative association is expected between Alzheimer’s disease and -863 
C/A polymorphism. However our results did not reveal such an association. 
CALHM1  gene  encodes a  multipass transmembrane  glycoprotein  that  controls  cytosolic 
Ca
2+  concentrations.  CALHM1  expression  controls  APP  processing  by  interfering  with 
extracellular Aβ accumulation. Also CALHM1 controls APP proteolysis in a Ca
2+ dependent 
manner.  According  to  Calcium  hypothesis  of  brain  aging  and  Alzheimer’s  disease 
neuropathological  changes  associated  with  AD  is  caused  by  changes  in  Ca
2+  homeostasis 
(KHACHATURIAN et al. 1989).  
It  had  been  shown  that  rs2986017  SNP  in  CALHM1  gene  (P86L)  is  associated  with 
increased risk of LOAD, significant dysregulation of Ca
2+ homeostasis and APP metabolism 
(DRESES-WERRINGLOER et al. 2008; SHOJI et al. 2005). In a US study, the impact of rs2986017 on 
the risk of developing AD in 2043 AD cases and 1361 controls Distribution of the T allele was 
increased in AD cases as compared to controls in all studies, with odds ratios (ORs) ranging 
from 1.29 to 1.99 (DRESES-WERRINGLOER et al. 2008). In a similar study a significant association 
was detected between CALHM1-P86L polymorphism and AD in the ethnic Chinese (CUI et al. 
2010).  In a study carried out in Spain a weak evidence of association between P86L mutation 
and LOAD susceptibility was observed when a recessive model was applied (P=0.24; OR=1.38, 
CI:  1.01-1.89)  (BOADA  et  al.  2010).  However  some  other  investigations  performed  on 
populations  from  other  ethnic  origins  have  reported  that  the  difference  between  the  above 
mentioned  polymorphism  and  LOAD  is  non-significant  (BERTRAM et al.  2008;  INOUE et  al. 
2010; NACMIAS et al. 2010). 
Our study corroborates the findings by different groups (P=0.008; OR=0.41, CI: 0.22-0.79) 
(BOADA et al. 2010; CUI et al. 2010; DRESES-WERRINGLOER et al. 2008). Even though our sample 
was much smaller than the original study, it showed an association with LOAD cases.  
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Izvod 
Cilj istraživanja je bio ispitivanje pet polimorfnih DNK markera: CCR2 (+190 G/A), CCR5∆32, 
TNF-α (-308 G/A), TNF-α (-863 C/A) i CALHM1 (+394 C/T I utvrđivanje odnosa polimorfnosti 
markera  i  rizika  kasne  pojave  Alchajmerove  bolesti  u  populaciji  Irana  –  istočnog  dela 
Azerbejdžana. U ispitivanja je uključeno ukupno 160 uzoraka obolelih pacijenata i 163 uzorka  
zdravih osoba. Genotipiziranje je vršeno ispitivanjem polimorfizma (PCR – RFLP) a rezultati su 
potvrđeni dvosmernim sekvenciranjem. Statističkom obradom rezultata nisu utvrđene značajne 
razlike učestalosti CCR5∆32 unutar controlne grupe. Isti rezultat je dobijen za  TNF-α (-863 
C/A) genotip i frekvece alela. Za razliku od navedenog utvrđene su statistički značajne razlike u 
frekvenci TNF-α (-308 G/A)  i CCR2-64I genotipova bolesnika i kontrolnih uzoraka. Utvrđena 
je niska statistički značajna razlika između alela i frekvence genotipa rs2986017 u CALHM1 
(+394 C/T; P86L) između pacijenata i kontrolnih uzoraka. Zaključeno je da T alel P86L varijante 
u  CALHM1  &  +190  G/A  alela CCR2  ima  zaštitnu  ulogu     za pojavu  abnormalnih  osobina 
Alzhajmerove bolesti 
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